Expression of Y-box-binding protein-1 and epithelialmesenchymal transition markers in colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2014.08.020

Abstract

Abstract: ObjectiveTo detect the expressions of Yboxbinding protein1 (YB1) and epithelialmesenchymal transition (EMT) markers (Ecadherin and Ncadherin) in colorectal cancer (CRC), to analyze the relationship between the expression of YB1 and clinicopathological parameters, to evaluate the correlations among YB1, Ecadherin and Ncadherin. MethodsThe expressions of YB1, Ecadherin and Ncadherin in 120 primary CRC tumors and corresponding normal tissues were detected by western blot and immunohistochemistry and the results were analyzed. ResultsThe expressions of YB1, Ecadherin and Ncadherin in tumors were significantly different from those in corresponding normal tissues (χ2=47.373, P＜0.05; χ2=83.145, P＜0.05;χ2=41.832, P＜0.05). The expression of YB1 in tumors was associated significantly with tumor differentiation, tumor invasion, lymph node metastasis and distance metastasis (χ2=8.077, P=0.008; χ2=8.178, P=0.006; χ2=15.152, P＜0.001; χ2=7.368, P=0.011). It was negatively correlated with Ecadherin expression (r=-0.238, P=0.009), but positively correlated with Ncadherin expression (r=0.361, P＜0.001). ConclusionYB1 may promote the occurrence and development of CRC by participating in EMT program.

Key words: Y-box-binding protein 1, Colorectal neoplasms, Epithelial-mesenchymal transition

Yan Xuebing, Yan Leilei, Liu Sihong, Shan Zezhi, Jin Zhiming. Expression of Y-box-binding protein-1 and epithelialmesenchymal transition markers in colorectal cancer[J]. Journal of International Oncology, 2014, 41(8): 624-628.

References

［1］ Lasham A, Print CG, Woolley AG, et al. YB1: oncoprotein, prognostic marker and therapeutic target?［J］. Biochem J, 2013, 449(1): 11-23. ［2］严雪冰, 朱庆超, 金志明. Y盒结合蛋白1与上皮间质转化［J］. 国际肿瘤学杂志, 2013, 40(12): 896-899. ［3］ Thiery JP, Acloque H, Huang RY, et al. Epithelialmesenchymal transitions in development and disease［J］. Cell, 2009, 139(5): 871-890. ［4］ Thiery JP. Epithelialmesenchymal transitions in tumour progression［J］. Nat Rev Cancer, 2002, 2(6): 442-454. ［5］ He X, Chen Z, Jia M, et al. Downregulated ECadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from metaanalysis［J］. PLoS One, 2013, 8(7): e70858. ［6］ Toiyama Y, Yasuda H, Saigusa S, et al. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer［J］. Carcinogenesis, 2013, 34(11): 2548-2557. ［7］ Todosi AM, Gavrilescu MM, Aniei GM, et al. Colon cancer at the molecular levelusefulness of epithelialmesenchymal transition analysis［J］. Rev Med Chir Soc Med Nat lasi, 2012, 116(4): 1106-1111. ［8］ Evdokimova V, Tognon C, Ng T, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB1 promotes an epithelialmesenchymal transition［J］. Cancer Cell, 2009, 15(5): 402-415. ［9］ Shiota M, Yokomizo A, Itsumi M, et al. Twist1 and Yboxbinding protein1 promote malignant potential in bladder cancer cells［J］. BJU Int, 2011, 108(2 Pt 2): E142-149. ［10］ Zhang H, Cheng S, Zhang M, et al. Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB1 protein expression［J］. Int J Oncol, 2014, 44(3): 769780. ［11］ Jürchott K, Kuban RJ, Krech T, et al. Identification of Ybox binding protein 1 as a core regulator of MEK/ERK pathwaydependent gene signatures in colorectal cancer cells［J］. PLoS Genet, 2010, 6(12): e1001231. ［12］ Tsofack SP, Garand C, Sereduk C, et al. NONO and RALY proteins are required for YB1 oxaliplatin induced resistance in colon adenocarcinoma cell lines［J］. Mol Cancer, 2011, 10: 145. ［13］ Cho SH, Park YS, Kim HJ, et al. CD44 enhances the epithelialmesenchymal transition in association with colon cancer invasion［J］. Int J Oncol, 2012, 41(1): 211-218. ［14］ To K, Fotovati A, Reipas KM, et al. Ybox binding protein1 induces the expression of CD44 and CD49f leading to enhanced selfrenewal, mammosphere growth, and drug resistance［J］. Cancer Res, 2010, 70(7): 2840-2851.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu. Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment [J]. Journal of International Oncology, 2022, 49(8): 490-493.